Eoflow (294090) Q3 2025 earnings summary

Executive summary

• Specializes in wearable drug delivery solutions, notably the EOPatch insulin pump, targeting the growing diabetes device market.

• Expanded product portfolio includes sensor-integrated artificial pancreas systems and cloud-based diabetes management software.

• Recent regulatory approvals in Korea and Europe, with ongoing R&D for next-generation devices.

Financial highlights

• Revenue for 2025 Q3: KRW 1.60 billion; cumulative 2025 revenue: KRW 3.50 billion, down from KRW 4.55 billion in the same period 2024.

• Operating loss for 2025 Q3: KRW -111.42 billion; net loss attributable to owners: KRW -122.16 billion (cumulative), compared to KRW -35.39 billion in 2024.

• Cash and cash equivalents at Q3-end: KRW 0.85 billion, down from KRW 3.39 billion at 2024 year-end.

• Equity turned negative: KRW -99.53 billion at Q3 2025, from KRW 5.46 billion at 2024 year-end.

Outlook and guidance

• Management is implementing cost controls, restructuring, and seeking new funding to address liquidity and going concern risks.

• Focus remains on expanding global sales and advancing R&D for next-generation diabetes devices.